Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mercedes Colorado

Showing results (11-20 of 44) with videos related to

Pageof 5
Sort By:
Bone Marrow Transplantation|October 10, 2022
Donor lymphocyte infusions after haploidentical stem cell transplantation with PTCY: A study on behalf of the EBMT cellular therapy & immunobiology working partyNicole Santoro, Jarl E Mooyaart, Raynier Devillier, et al.
European Journal of Haematology|April 4, 2020
Acute myeloid leukemia with inv(3)(q21.3q26.2)/t(3;3)(q21.3;q26.2): Study of 61 patients treated with intensive protocolsMarta Sitges, Blanca Boluda, Ana Garrido, et al.
Transplantation and Cellular Therapy|July 9, 2026
FEASIBILITY AND INTERIM SAFETY AND EFFICACY ANALYSIS OF A FAST AUTOMATED PRODUCTION OF PROPHYLACTIC CMV-SPECIFIC CTLs AFTER ALLOGENEIC HSCTMa Aránzazu Bermúdez, Oscar M Pello, Miriam Sánchez-Escamilla, et al.
Haematologica|March 23, 2023
Graft-<i>versus</i>-host disease and relapse/rejection-free survival after allogeneic transplantation for idiopathic severe aplastic anemia: a comprehensive analysis from the SAAWP of the EBMTRaynier Devillier, Dirk-Jan Eikema, Carlo Dufour, et al.
Leukemia Research|December 22, 2015
Feasibility and results of subtype-oriented protocols in older adults and fit elderly patients with acute lymphoblastic leukemia: Results of three prospective parallel trials from the PETHEMA groupJosep-Maria Ribera, Olga García, Albert Oriol, et al.
Bone Marrow Transplantation|February 16, 2022
Autologous hematopoietic cell transplantation for relapsed multiple myeloma performed with cells procured after previous transplantation-study on behalf of CMWP of the EBMTJoanna Drozd-Sokołowska, Luuk Gras, Nienke Zinger, et al.
Annals of Hematology|June 24, 2025
Prognostic factors of survival in second allogeneic hematopoietic transplantationRodrigo Cantera Estefanía, Raquel García Ruiz, Sara Fernández-Luis, et al.
British Journal of Haematology|December 15, 2018
Bendamustine as part of conditioning of autologous stem cell transplantation in patients with aggressive lymphoma: a phase 2 study from the GELTAMO groupAlba M Redondo, David Valcárcel, Ana P González-Rodríguez, et al.
Transplantation and Cellular Therapy|February 2, 2022
Post-Transplantation Cyclophosphamide After HLA Identical Compared to Haploidentical Donor Transplant in Acute Myeloid Leukemia: A Study on Behalf of GETH-TCRebeca Bailén, María Jesús Pascual-Cascón, Manuel Guerreiro, et al.
Leukemia Research|March 14, 2022
Acute leukemia arising from myeloproliferative or myelodysplastic/myeloproliferative neoplasms: A series of 372 patients from the PETHEMA AML registryJuan-Carlos Hernández-Boluda, David Martínez-Cuadrón, Arturo Pereira, et al.
Pageof 5

Showing results (11-20 of 44) with videos related to

Sort By:
Pageof 5
Bone Marrow Transplantation|October 10, 2022
Donor lymphocyte infusions after haploidentical stem cell transplantation with PTCY: A study on behalf of the EBMT cellular therapy & immunobiology working partyNicole Santoro, Jarl E Mooyaart, Raynier Devillier, et al.
European Journal of Haematology|April 4, 2020
Acute myeloid leukemia with inv(3)(q21.3q26.2)/t(3;3)(q21.3;q26.2): Study of 61 patients treated with intensive protocolsMarta Sitges, Blanca Boluda, Ana Garrido, et al.
Transplantation and Cellular Therapy|July 9, 2026
FEASIBILITY AND INTERIM SAFETY AND EFFICACY ANALYSIS OF A FAST AUTOMATED PRODUCTION OF PROPHYLACTIC CMV-SPECIFIC CTLs AFTER ALLOGENEIC HSCTMa Aránzazu Bermúdez, Oscar M Pello, Miriam Sánchez-Escamilla, et al.
Haematologica|March 23, 2023
Graft-<i>versus</i>-host disease and relapse/rejection-free survival after allogeneic transplantation for idiopathic severe aplastic anemia: a comprehensive analysis from the SAAWP of the EBMTRaynier Devillier, Dirk-Jan Eikema, Carlo Dufour, et al.
Leukemia Research|December 22, 2015
Feasibility and results of subtype-oriented protocols in older adults and fit elderly patients with acute lymphoblastic leukemia: Results of three prospective parallel trials from the PETHEMA groupJosep-Maria Ribera, Olga García, Albert Oriol, et al.
Bone Marrow Transplantation|February 16, 2022
Autologous hematopoietic cell transplantation for relapsed multiple myeloma performed with cells procured after previous transplantation-study on behalf of CMWP of the EBMTJoanna Drozd-Sokołowska, Luuk Gras, Nienke Zinger, et al.
Annals of Hematology|June 24, 2025
Prognostic factors of survival in second allogeneic hematopoietic transplantationRodrigo Cantera Estefanía, Raquel García Ruiz, Sara Fernández-Luis, et al.
British Journal of Haematology|December 15, 2018
Bendamustine as part of conditioning of autologous stem cell transplantation in patients with aggressive lymphoma: a phase 2 study from the GELTAMO groupAlba M Redondo, David Valcárcel, Ana P González-Rodríguez, et al.
Transplantation and Cellular Therapy|February 2, 2022
Post-Transplantation Cyclophosphamide After HLA Identical Compared to Haploidentical Donor Transplant in Acute Myeloid Leukemia: A Study on Behalf of GETH-TCRebeca Bailén, María Jesús Pascual-Cascón, Manuel Guerreiro, et al.
Leukemia Research|March 14, 2022
Acute leukemia arising from myeloproliferative or myelodysplastic/myeloproliferative neoplasms: A series of 372 patients from the PETHEMA AML registryJuan-Carlos Hernández-Boluda, David Martínez-Cuadrón, Arturo Pereira, et al.
Pageof 5